# Preemptive Analgesia for Primary Dysmenorrhoea

> **NCT03323671** · PHASE2,PHASE3 · COMPLETED · sponsor: **Hanan Nabil** · enrollment: 84 (actual)

## Conditions studied

- Primary Dysmenorrhea

## Interventions

- **DRUG:** preemptive mefenamic acid
- **DRUG:** mefenamic acid

## Key facts

- **NCT ID:** NCT03323671
- **Lead sponsor:** Hanan Nabil
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-01
- **Primary completion:** 2017-12-01
- **Final completion:** 2017-12-01
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2017-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03323671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03323671, "Preemptive Analgesia for Primary Dysmenorrhoea". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03323671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*